GUID: BSFD8858-33DC-4DD5-9403-CAF283CC25D5Allegations of OLC lawyers facilitating Geneva Convention violations
1 duplicate copy in the archive
Sanofi ODYSSEY Phase 3 Clinical Trial Overview for Praluent
Title Matchkaggle-ho-025892
Case Filed-33620House OversightSanofi ODYSSEY Phase 3 Clinical Trial Overview for Praluent
November 11, 20251p4 persons
Case File
d-33620House OversightSanofi ODYSSEY Phase 3 Clinical Trial Overview for Praluent
Other
The passage is a standard pharmaceutical promotional document describing clinical trial results and safety information for Praluent. It contains no allegations, financial flows, or connections to high ODYSSEY Phase 3 includes 14 global trials with >23,500 patients. Primary endpoint met: LDL cholesterol reduction at week 24. ODYSSEY OUTCOMES trial enrolling ~18,000 patients.
Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #025892
Pages
1
Persons
4
Integrity
No Hash Available
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.